Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA

Journal of Neurosurgery

Volumn 92, Issue 2, 2000, Pages 297-305

  Halatsch, Marc Eric ^a,b   Schmidt, Ursula ^a   Bötefür, Ingolf C ^a   Holland, James F ^a   Ohnuma, Takao ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Deletion mutant epidermal growth factor receptor; Glioblastoma multiforme; Hairpin ribozyme; Retrovirus mediated DNA transfer tumorigenicity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; RIBOZYME;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL STRAIN 3T3; DNA TRANSFER; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033964013     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2000.92.2.0297     Document Type: Article

References (37)

1. met gene. Nucleic Acids Res 12:1101-1115, 1984
2. Cepco C: Preparation of a specific retrovirus producer cell line, in Chanda VB (ed): Current Protocols in Molecular Biology. New York: John Wiley & Sons, 1995, Vol 2, pp 9.11.1-9.11.13
3. Chowrira BM, Berzal-Herranz A, Burke JM: Ionic requirements for RNA binding, cleavage, and ligation by the hairpin ribozyme. Biochemistry 32:1088-1095, 1993
4. Cotten M, Birnstiel ML: Ribozyme mediated destruction of RNA in vivo. EMBO J 8:3861-3866, 1989
5. Culver KW, Van Gilder J, Link CJ, et al: Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 5:343-379, 1994
6. DeYoung MB, Siwkowski AM, Lian Y, et al: Catalytic properties of hairpin ribozymes derived from chicory yellow mottle virus and arabis mosaic virus satellite RNAs. Biochemistry 34: 15785-15791, 1995
7. Dorai T, Kobayashi H, Holland JF, et al: Modulation of platelet-derived growth factor-β mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol 46:437-444, 1994
8. Ekstrand AJ, Sugawa N, James CD, et al: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309-4313, 1992
9. Fischer U, Meltzer P, Meese E: Twelve amplified and expressed genes localized in a single domain in glioma. Hum Genet 98:625-628, 1996
10. Frykberg L, Palmieri S, Beug H, et al: Transforming capacities of avian erythroblastosis virus mutants deleted in the erbA or erbB oncogenes. Cell 32:227-238, 1983
11. Halatsch ME, Bötefür IC, Schmidt U, et al: Design and in vitro evaluation of hairpin ribozymes against deletion-mutant epidermal growth factor receptor RNA for prospective glioblastoma gene therapy. Mt Sinai J Med 65:70, 1998 (Abstract)
12. Halatsch ME, Holland JF, Ohnuma T: Cleavage of glioma-specific deletion-mutant epidermal growth factor receptor (EGFR) mRNA by a hairpin ribozyme. Proc Am Assoc Cancer Res 38:474, 1997 (Abstract)
13. Halatsch ME, Schmidt U, Holland JF, et al: Reversal of the malignant phenotype of glioblastoma cells by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor mRNA. Proc Am Assoc Cancer Res 40:593, 1999 (Abstract)
14. Hantzopoulos PA, Sullenger BA, Ungers G, et al: Improved gene expression upon transfer of the adenosine deaminase minigene outside of the transcriptional unit of a retroviral vector. Proc Natl Acad Sci USA 86:3519-3523, 1989
15. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334: 585-591, 1988
16. Huang HJS, Nagane M, Klingbeil CK, et al: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927-2935, 1997
17. Humphrey PA, Wong AJ, Vogelstein B, et al: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87:4207-4211, 1990
18. Kobayashi H, Kim N, Halatsch ME, et al: Specificity of ribozyme designed for mutated DHFR mRNA. Biochem Pharmacol 47:1607-1613, 1994
19. Long DM, Uhlenbeck OC: Self-cleaving catalytic RNA. FASEB J 7:25-30, 1993
20. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-406, 1988
21. Nagane M, Coufal F, Lin H, et al: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086, 1996
22. Nilsen TW, Maroney PA, Goodwin RG, et al: c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an ami no-truncated EGF receptor. Cell 41:719-726, 1985
23. Nishikawa R, Ji XD, Harmon RC, et al: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727-7731, 1994
24. Pawson T: Protein modules and signalling networks. Nature 373:573-580, 1995
25. Schlegel J, Merdes A, Stumm G, et al: Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77, 1994
26. Shapiro WR: Therapy of adult malignant brain tumors: what have the clinical trials taught us. Semin Oncol 13:38-45, 1986
27. Su YA, Ray ME, Lin T, et al: Reversion of monochromosome-mediated suppression of tumorigenicity in malignant melanoma by retroviral transduction. Cancer Res 56: 3186-3191, 1996
28. Sugawa N, Ekstrand AJ, James CD, et al: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606, 1990
29. Sullenger BA, Lee TC, Smith CA, et al: Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol 10:6512-6523, 1990
30. Thompson JD, Ayers DF, Malmstrom TA, et al: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res 23:2259-2268, 1995
31. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418-425, 1984
32. Wikstrand CJ, McLendon RE, Friedman AH, et al: Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57: 4130-4140, 1997
33. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89:2965-2969, 1992
34. Yamazaki H, Kijima H, Ohnishi Y, et al: Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 90:581-587, 1998
35. Yamazaki H, Ohba Y, Tamaoki N, et al: A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn J Cancer Res 81:773-779, 1990
36. Yuyama N, Ohkawa J, Inokuchi Y, et al: Construction of a tRNA-embedded-ribozyme trimming plasmid. Biochem Biophys Res Comm 186:1271-1279, 1992
37. met. Nature 300:81-84, 1982